Former OpenAI Executive Says Smarter AI Models Alone Won't Cure Diseases
Former OpenAI executive Fidji Simo agreed with Anthropic CEO Dario Amodei, stating that curing diseases with AI requires high-quality biological datasets and infrastructure, not just smarter models. Simo, who co-founded the biotech startup ChronicleBio, emphasized that the lack of structured biological data is the primary bottleneck for treating complex chronic illnesses. This highlights a shift in the AI industry from making grand promises to addressing the practical bottlenecks of data scarcity in specialized fields like healthcare. It underscores that the future of AI in medicine depends heavily on building domain-specific biological infrastructure rather than relying solely on general LLM scaling. Simo noted that while cancer research benefits from decades of rich datasets in genomics and pathology, complex chronic conditions like Postural Orthostatic Tachycardia Syndrome (POTS) lack similar data infrastructure. Consequently, her startup ChronicleBio is focusing on generating these essential datasets to enable AI-driven drug discovery for neuroimmune and chronic conditions.
## BACKGROUND
Postural Orthostatic Tachycardia Syndrome (POTS) is a complex disorder of the autonomic nervous system that causes an abnormal heart rate increase upon standing, making it difficult to diagnose and treat. ChronicleBio is a biotechnology company co-founded by Simo that aims to integrate data, biology, and AI to discover treatments for such complex chronic and neuroimmune conditions.